Patient # | Prior regimen | Line of therapy | Duration of treatment (first to last dose) | Number of cycles administered | Best response | Reason for discontinuation |
1 | Chemotherapy | |||||
Carboplatin/Gemcitabine | 1L | 120 days (=4 months) | 6 | Progressive disease | Progression/Recurrence | |
Gemcitabine | Maintenance | 33 days (=1 month, 2 days) | 1 | Progressive disease | Progression/Recurrence | |
Carboplatin/Pemetrexed | 2L | 92 days (=3 months, 3 days) | 4 | Progressive disease | Progression/Recurrence | |
CPI | ||||||
Nivolumab | 3L | 570 days (=1 year, 10 months) | 40 | Stable disease | Progression/Recurrence | |
2 | Chemotherapy | |||||
Carboplatin/Paclitaxel | 1L | 50 days (=1 month, 22 days) | 2 | Stable disease | Progression/Recurrence | |
CPI | ||||||
Atezolizumab | 2L | 64 days (=2 months, 3 days) | 4 | Progressive disease | Progression/Recurrence |
CPI, checkpoint inhibitor; 1L, first line; 2L, second line; 3L, third line; NSCLC, non–small cell lung cancer; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.